A MULTICENTER RANDOM ASSIGNMENT PHASE II STUDY OF IRINOTECAN AND ALVOCIDIB (FLAVOPIRIDOL) VERSUS IRINOTECAN ALONE FOR PATIENTS WITH P53 WILD TYPE GASTRIC ADENOCARCINOMA (NCI 8060).

Trial Profile

A MULTICENTER RANDOM ASSIGNMENT PHASE II STUDY OF IRINOTECAN AND ALVOCIDIB (FLAVOPIRIDOL) VERSUS IRINOTECAN ALONE FOR PATIENTS WITH P53 WILD TYPE GASTRIC ADENOCARCINOMA (NCI 8060).

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2014

At a glance

  • Drugs Alvocidib (Primary) ; Irinotecan (Primary)
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 May 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 06 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 05 Jun 2012 Interim results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top